Complaints About Advertising Of Medicines, UK
Main Category: Litigation / Medical MalpracticeArticle Date: 22 Jul 2008 - 1:00 PDT
The outcomes of the investigations into four complaints about the advertising of medicines have been published:
Cases upheld
-- Calpol Night (paracetamol & diphenhydramine hydrochloride) and CalCough Chesty (guaiphenesin) - Calpol website - June 2008
-- Artelac (hypromellose) 0.32% Eye Drops, supply of samples - April and June 2008
Cases not upheld
-- Omacor (omega-3-acid ethyl esters), Healthcare Professionals - June 2008
-- Direct to Consumer advertising - Paling Walters website - June 2008
The MHRA (Medicines and Healthcare products Regulatory Agency) is the (UK) government agency responsible for ensuring that medicines and medical devices work, and are acceptably safe. No product is risk-free. Underpinning all our work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks. We keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem. We encourage everyone - the public and healthcare professionals as well as the industry - to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. www.mhra.gov.uk
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |





